Transforming lung cancer diagnostics with a non-invasive breath analysis technology, offering a more accurate alternative to CT scans. Developed from Gates Foundation-funded research, their patented test detects cancer biomarkers in exhaled breath with 94% sensitivity and 85% specificity.
It reduces unnecessary procedures and healthcare costs, poised to disrupt the $107B global cancer diagnostics market. Early feasibility studies have shown promise in using their platform for identifying COVID-19 and pneumonia, demonstrating its versatility. With further development, the technology could be adapted to screen for various cancers and respiratory conditions, making it a powerful tool in early disease detection.
With future plans to expand into detecting other diseases like COVID-19 and pneumonia, their versatile platform offers significant growth potential, making it an exceptional investment opportunity backed by strong clinical validation.
Let us know, if you'd like to request more information about the company, or if you'd like to hear a great pitch first.
Contact Us